Nanjing Hicin Pharmaceutical Co., Ltd.

300584

CNE100002F44

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 28/05/2024 am IST			5-day change	1st Jan Change
16.72 ^CNY	-1.76%		-6.54%	-28.18%

25/04	Nanjing Hicin Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2023	CI
24/04	Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Nanjing Hicin Pharmaceutical Plans To Acquire 90% Stake In Nerviano Medical Sciences With Partners

November 26, 2017 at 10:30 am IST

Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) said it and partners plan to acquire 90% stake in Nerviano Medical Sciences S.r.l. Nanjing Hicin Pharmaceutical said it and partners plan to set up industry fund worth CNY 600 million to invest in Nerviano Medical Sciences.

Latest news about Nanjing Hicin Pharmaceutical Co., Ltd.

Nanjing Hicin Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2023	25/04	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/23/26	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	22/23/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/23/24	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Nanjing Hicin Pharmaceutical Co., Ltd. cancelled the transaction announced on June 10, 2022	13/23/13	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Management Changes	19/22/19	CI
Nanjing Hicin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 400 million in funding	10/22/10	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for the Year 2021, Payable on May 25, 2022	20/22/20	CI
Nanjing Hicin Pharmaceutical Approves Profit Distribution for 2021	18/22/18	CI
Nanjing Hicin Pharmaceutical Proposes Profit Distribution for 2021	23/22/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	21/22/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	25/21/25	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	03/21/03	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 13, 2021	01/21/01	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2020	09/21/09	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	07/21/07	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	29/20/29	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	17/20/17	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces 2019 Final Distribution Plan to Be Implemented (A Shares), Payable on May 14, 2020	08/20/08	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Approves the Final Cash Dividend for the Year 2019	01/20/01	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	20/20/20	CI

Chart Nanjing Hicin Pharmaceutical Co., Ltd.

Duration

Period

Chart Nanjing Hicin Pharmaceutical Co., Ltd.

More charts

Company Profile

Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NANJING HICIN PHARMACEUTICAL CO., LTD.	-28.18%	28Cr
ELI LILLY AND COMPANY	+37.47%	73TCr
JOHNSON & JOHNSON	-7.87%	35TCr
MERCK & CO., INC.	+15.58%	33TCr
ABBVIE INC.	-0.38%	28TCr
ASTRAZENECA PLC	+13.47%	24TCr
NOVARTIS AG	+7.35%	21TCr
ROCHE HOLDING AG	-6.42%	20TCr
AMGEN INC.	+3.85%	16TCr
PFIZER, INC.	-2.10%	16TCr

Other Pharmaceuticals

Nanjing Hicin Pharmaceutical Co., Ltd.

Equities

300584

CNE100002F44

Pharmaceuticals

Nanjing Hicin Pharmaceutical Plans To Acquire 90% Stake In Nerviano Medical Sciences With Partners

Latest news about Nanjing Hicin Pharmaceutical Co., Ltd.

Chart Nanjing Hicin Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals